Next Article in Journal
Ureidopyridazine Derivatives as Acyl-CoA: cholesterol acyltransferase Inhibitors
Previous Article in Journal
Enhanced Role of Grapefruit Juice on the Anti-schistosomal Activity of Artemether on the Liver of Schistosoma haematobium Infected Hamsters
Article Menu

Article Versions

Export Article

Scientia Pharmaceutica is published by MDPI from Volume 84 Issue 3 (2016). Articles in this Issue were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence. Articles are hosted by MDPI on as a courtesy and upon agreement with Austrian Pharmaceutical Society (Österreichische Pharmazeutische Gesellschaft, ÖPhG).
Open AccessArticle
Sci. Pharm. 2008, 76(2), 171-184; (registering DOI)

Tirofiban Preserves Endothelial Junctions and Decreases Endothelin-1

Department of Cardiology, Cardiovascular Institute and Fu-Wai Heart Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Author to whom correspondence should be addressed.
Received: 22 March 2008 / Accepted: 6 May 2008 / Published: 11 May 2008
PDF [319 KB, uploaded 27 December 2016]


It has been verified that glycoprotein IIb/IIIa inhibitor tirofiban can attenuate myocardial no-reflow. Myocardial no-reflow has been associated with alterations in endothelial junctions. In addition, ET-1 is an important mechanism for myocardial no-reflow. However, the effect of tirofiban on endothelial junctions and Endothelin-1 (ET-1) is unknown. Methods: Twenty-eight mini-swines were randomized into 3 study groups: 10 in control, 10 given an intravenous infusion of tirofiban and 8 in sham-operated. Acute myocardial infarction and reperfusion model was created with three-hour occlusion of the left anterior descending coronary artery followed by one-hour reperfusion. Results: In control group, plasma ET-1 significantly increased, ET-1 or VE-cadherin level in the reflow and no-reflow myocardium was significantly higher or lower than that in normal myocardium. Compared with the control group, tirofiban significantly decreased plasma ET-1 and myocardial tissue ET-1, maintained VE-cadherin level. Conclusions: Tirofiban is effective in preserving endothelial junction. This beneficial effect of tirofiban could be partly due to its reduction of ET-1.
Keywords: Acute myocardial infarction; Endothelin-1; Reperfusion; Tirofiban; No-reflow Acute myocardial infarction; Endothelin-1; Reperfusion; Tirofiban; No-reflow
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

ZHAO, J.-L.; YANG, Y.-J.; PEI, W.-D.; SUN, Y.-H.; ZHAI, M.; LIU, Y.-X.; GAO, R.-L. Tirofiban Preserves Endothelial Junctions and Decreases Endothelin-1. Sci. Pharm. 2008, 76, 171-184.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics



[Return to top]
Sci. Pharm. EISSN 2218-0532 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top